Beludavimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A neutralizing human monoclonal antibody directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, beludavimab specifically targets and binds to an epitope on the SARS-CoV-2 S protein that is shared with SARS-CoV-1, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. Beludavimab may also enhance virus-specific T-cell activity. Altogether, this may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.

**Synonyms:** - BELUDAVIMAB - GSK 4182137 - GSK-4182137 - GSK4182137 - VIR 7832 - VIR-7832 - VIR7832